⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MNPR News
Monopar Therapeutics Inc. Common Stock
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
globenewswire.com
MNPR
Form 8-K
sec.gov
MNPR
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
globenewswire.com
MNPR
Form 8-K
sec.gov
MNPR
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
globenewswire.com
MNPR
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
globenewswire.com
MNPR
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
globenewswire.com
MNPR
Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025
globenewswire.com
MNPR
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
globenewswire.com
MNPR